Blinatumomab for the treatment of B-cell lymphoma

Expert Opinion on Investigational Drugs
Eunhye Oak, Nancy L Bartlett

Abstract

Blinatumomab is a bispecific T-cell engager (BiTE) molecule that recruits cytotoxic T cells to target tumor B cells by linking the CD3 and CD19 antigens. Among the various formats of bispecific antibodies developed in the past 50 years, the BiTE class is remarkable for its low effector-to-target ratio, high tissue penetration and singular ability to activate T cells independent of MHC class I presentation or costimulation. Blinatumomab has been studied in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and B-precursor acute lymphoblastic leukemia (B-ALL). This article reviews the current literature on blinatumomab including its pharmacology, preclinical findings, clinical trials in B-cell NHL and, to a lesser extent, Phase II studies in B-ALL. The authors discuss the potential future directions in light of other new competing therapies for NHL and unmet clinical needs in the market. The recent approval of blinatumomab for B-ALL symbolizes a breakthrough for BiTE technology with prospective application in the targeted therapy of other cancers. Although blinatumomab seems an unlikely option for treating indolent lymphoma due to toxicity, the need for long-term continuous infusion therapy and multiple promising w...Continue Reading

References

Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C GuglielmiF Chauvin
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Patrick HoffmannPatrick A Baeuerle
Oct 11, 2005·Drug Discovery Today·Evelyn WolfPatrick A Baeuerle
Dec 1, 2006·Annual Review of Immunology·Gabriel A RabinovichEduardo M Sotomayor
Oct 24, 2008·Haematologica·Alejandro MartínUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group)
Aug 14, 2009·Journal of Hematology & Oncology·Venumadhav KotlaAmit Verma
Mar 23, 2011·Experimental Cell Research·Dirk Nagorsen, Patrick A Baeuerle
Mar 28, 2012·Cancer Cell International·Ana M Soto, Carlos Sonnenschein
Jun 21, 2012·Blood·Jennifer A WoyachJohn C Byrd
Jul 28, 2012·Lancet·Kate R ShanklandBarry W Hancock
Sep 4, 2012·Pharmacology & Therapeutics·Dirk NagorsenRalf Bargou
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Oct 16, 2012·Blood Reviews·Matthew A Lunning, Julie M Vose
Feb 5, 2013·Critical Reviews in Oncology/hematology·Maurizio MartelliStefano A Pileri
Apr 3, 2013·Nature Reviews. Clinical Oncology·James N Kochenderfer, Steven A Rosenberg
Apr 24, 2013·Therapeutic Advances in Hematology·Michele MerliFrancesco Passamonti
Apr 30, 2013·Current Opinion in Chemical Biology·Stanley R Frankel, Patrick A Baeuerle
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyThomas E Witzig
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Sep 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul J MartinAl Benson
Nov 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Max S ToppRalf C Bargou

❮ Previous
Next ❯

Citations

Feb 2, 2016·Cancer Biology & Therapy·Bin DongZhong Wang
Oct 9, 2015·Journal of Immunotherapy·Li LiQing Li
Sep 16, 2015·Immunotherapy·Yu-Tzu Tai, Kenneth C Anderson
Jun 27, 2015·Biochemical and Biophysical Research Communications·Felipe Vences-CatalánShoshana Levy
Dec 13, 2017·Journal of Immunotherapy·Wentong DengZhong Wang
Nov 2, 2018·Human Vaccines & Immunotherapeutics·Richard BurtAdele K Fielding
Oct 18, 2015·Journal of Experimental & Clinical Cancer Research : CR·Francesca FerrariAlessandro D Santin
Sep 10, 2021·Immunotherapy·Essam A TawfikNada M Zaidan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.